Belumosudil - Kadmon Pharmaceuticals
Alternative Names: Belumosudil mesylate - Kadmon Pharmaceuticals; BN-101; KD-025; KD025 mesylate; ME-3208; REZUROCK; Rholistiq; SAR445761; SLX-2119Latest Information Update: 07 May 2025
At a glance
- Originator Surface Logix
- Developer BK Pharmaceuticals; Kadmon Pharmaceuticals; Romeck Pharma
- Class Acetamides; Amines; Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Hepatoprotectants; Indazoles; Phenyl ethers; Quinazolines; Skin disorder therapies; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Graft-versus-host disease
- Registered Lung transplant rejection
- Phase II Idiopathic pulmonary fibrosis; Systemic scleroderma
- Phase I Autoimmune disorders
- Preclinical Multiple myeloma
- Discontinued Cancer; Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 24 Apr 2025 Launched for Graft-versus-host disease in South Korea (PO)
- 24 Apr 2025 Registered for Graft-versus-host disease (In adolescents, In adults, Treatment-experienced) in Taiwan (PO)
- 28 Jan 2025 Registered for Graft-versus-host disease in South Korea (PO) (Meiji Seika Pharma pipeline, January 2025)